AAAAAA
Results:
1-10
|
Results: 10
Authors:
Whitehead, RP
Unger, JM
Flaherty, LE
Eckardt, JR
Taylor, SA
Didolkar, MS
Samlowski, W
Sondak, VK
Citation: Rp. Whitehead et al., Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy - A Southwest Oncology Group study, INV NEW DR, 19(3), 2001, pp. 239-243
Authors:
Eckardt, JR
Citation: Jr. Eckardt, Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer, ONCOL-BASEL, 61, 2001, pp. 30-34
Authors:
Eckardt, JR
Citation: Jr. Eckardt, Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy, ONCOL-BASEL, 61, 2001, pp. 42-46
Authors:
Britten, CD
Rowinsky, EK
Baker, SD
Agarwala, SS
Eckardt, JR
Barrington, R
Diab, SG
Hammond, LA
Johnson, T
Villalona-Calero, M
Fraass, U
Statkevich, P
Von Hoff, DD
Eckhardt, SG
Citation: Cd. Britten et al., A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies, CLIN CANC R, 5(7), 1999, pp. 1629-1637
Authors:
Gerrits, CJH
Schellens, JHM
Burris, H
Eckardt, JR
Planting, AST
van der Burg, MEL
Rodriguez, GI
Loos, WJ
van Beurden, V
Hudson, I
Von Hoff, DD
Verweij, J
Citation: Cjh. Gerrits et al., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin), CLIN CANC R, 5(1), 1999, pp. 69-75
Authors:
Hammond, LA
Eckardt, JR
Baker, SD
Eckhardt, SG
Dugan, M
Forral, K
Reidenberg, P
Statkevich, P
Weiss, GR
Rinaldi, DA
Von Hoff, DD
Rowinsky, EK
Citation: La. Hammond et al., Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies, J CL ONCOL, 17(8), 1999, pp. 2604-2613
Authors:
Eckhardt, SG
Rizzo, J
Sweeney, KR
Cropp, G
Baker, SD
Kraynak, MA
Kuhn, JG
Villalona-Calero, MA
Hammond, L
Weiss, G
Thurman, A
Smith, L
Drengler, R
Eckardt, JR
Moczygemba, J
Hannah, AL
Von Hoff, DD
Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, J CL ONCOL, 17(4), 1999, pp. 1095-1104
Authors:
Fossella, FV
Green, MR
Eckardt, JR
Wozniak, AJ
Socinski, MA
Murren, JR
Citation: Fv. Fossella et al., Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer - Discussion I, SEMIN ONCOL, 26(5), 1999, pp. 41-42
Authors:
Lima, CMSR
Eckardt, JR
Leong, SS
Sherman, CA
Perkel, JA
Putman, T
Safa, AR
Bahadori, HR
Green, MR
Citation: Cmsr. Lima et al., Single-agent gemcitabine and gemcitabine/irinotecan combination (IrimoGem)in non-small cell lung cancer, SEMIN ONCOL, 26(5), 1999, pp. 43-50
Authors:
Eckardt, JR
Green, MR
Gralla, RJ
Langer, CJ
Eastman, A
Socinski, MA
Citation: Jr. Eckardt et al., Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer - Discussion II, SEMIN ONCOL, 26(5), 1999, pp. 71-72
Risultati:
1-10
|